Xeroderma Pigmentosum: Clinical Trials

12 trials for Xeroderma Pigmentosum, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 unknown, 1 enrolling by invitation, 1 recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Unknown 2, Terminated 1
Not applicable1Completed 1
Phase 11Withdrawn 1

Follow Xeroderma Pigmentosum: new trials by email Literature Review of Xeroderma Pigmentosum trials Research Report on Xeroderma Pigmentosum

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Reproductive Options in Inherited Skin Diseases
Ichthyosis, Palmoplantar Keratoses
Enrolling by invitationMaastricht University Medical Center6502024-01-012025-05-18
Natural History Study for DNA Repair Disorders
Interval History, Physical Examination, ECAB Assessment - DNA Repair Disorder, Cockayne Syndrome
RecruitingUniversity of Minnesota402022-10-012026-05-27
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62022-03-282023-09-21
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)
Afamelanotide - Xeroderma Pigmentosum
Phase 2UnknownClinuvel Europe Limited62021-10-192023-06-18
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Phase 1WithdrawnNational Cancer Institute (NCI)2021-05-112026-06-10
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma
Phase 2TerminatedSol-Gel Technologies, Ltd.502019-12-202026-07-21
Epidemiological Description of the Kaposi's Disease in France's Southeast
Kaposi's Disease
UnknownDirection Centrale du Service de Santé des Armées1002018-08-012019-05-14
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions
XPAND - Xeroderma Pigmentosum
Not applicableCompletedGuy's and St Thomas' NHS Foundation Trust152018-03-302020-07-22
Xeroderma Pigmentosum Patient Experiences
Survey Study - Xeroderma Pigmentosum
UnknownHenry Ford Health System152009-07-012010-05-14
Use of an SPF30 Sunscreen and an After-sun-lotion in Skin Cancer Risk Patients
Skin Cancer, Xeroderma Pigmentosum
CompletedMedical University of Graz132004-10-012009-09-30
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
Xeroderma Pigmentosum, Basal Cell Carcinoma
CompletedNational Cancer Institute (NCI)3012003-04-072024-01-08
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy
Cockayne Syndrome, Skin Neoplasms
CompletedNational Cancer Institute (NCI)7091999-05-102026-11-09

Narrower conditions

Basal Cell Nevus Syndrome (3)  ·  Skin Neoplasms (3)  ·  Carcinoma, Basal Cell (2)  ·  Cockayne Syndrome (2)  ·  Trichothiodystrophy Syndromes (2)  ·  Albinism (1)  ·  Birt-Hogg-Dube Syndrome (1)  ·  Carcinoma, Squamous Cell (1)  ·  Central Nervous System Neoplasms (1)  ·  Colorectal Neoplasms, Hereditary Nonpolyposis (1)  ·  Cutis Laxa (1)  ·  DNA Repair-Deficiency Disorders (1)  ·  Ectodermal Dysplasia (1)  ·  Epidermolysis Bullosa (1)

Broader conditions

Congenital Abnormalities (12)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12)  ·  Genetic Diseases, Inborn (12)  ·  Metabolic Diseases (12)  ·  Neoplasms (12)  ·  Nutritional and Metabolic Diseases (12)  ·  Photosensitivity Disorders (12)  ·  Pigmentation Disorders (12)  ·  Precancerous Conditions (12)  ·  Skin Abnormalities (12)  ·  Skin Diseases (12)  ·  Skin and Connective Tissue Diseases (12)  ·  DNA Repair-Deficiency Disorders (11)  ·  Skin Diseases, Genetic (11)  ·  Abnormalities, Multiple (5)

Interventions

afamelanotide (2)  ·  CTLA-4 Antigen (1)  ·  Ipilimumab (1)  ·  Longitudinal Studies (1)  ·  Nivolumab (1)  ·  Restraint, Physical (1)  ·  Specimen Handling (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Clinuvel Europe Limited (2)  ·  Direction Centrale du Service de Santé des Armées (1)  ·  Guy's and St Thomas' NHS Foundation Trust (1)  ·  Henry Ford Health System (1)  ·  Maastricht University Medical Center (1)  ·  Medical University of Graz (1)  ·  Sol-Gel Technologies, Ltd. (1)  ·  University of Minnesota (1)

Countries

United States (6)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  France (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Antoni Gostynski, MD, PhD (1)  ·  Daniel A Morgenstern (1)  ·  Henry W Lim, M.D. (1)  ·  John Weinman, PhD, FbPsS (1)  ·  Kenneth H Kraemer, M.D. (1)  ·  Michael R Sargen, M.D. (1)  ·  Peter Kang, MD (1)  ·  Peter Wolf, MD (1)  ·  Robert Sarkany, FRCP MD CCST (1)

Results publications

PMID 24918982, PMID 31320353, PMID 31503159

NIH funding

P30CA015704 (1), UM1CA154967 (1)